• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
OTC Pharmaceuticals in United Arab Emirates - Product Image

OTC Pharmaceuticals in United Arab Emirates

  • ID: 2113055
  • September 2014
  • Region: United Arab Emirates
  • 39 pages
  • MarketLine

Introduction

OTC Pharmaceuticals in United Arab Emirates industry profile provides top-line qualitative and quantitative summary information including: market size (value 2009-13, and forecast to 2018). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market. Essential resource for top-line data and analysis covering the United Arab Emirates otc pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Highlights:

- The OTC pharmaceuticals market consists of the retail sale of traditional medicines, cough and cold preparations (tablets, mixtures, lozenges, topical remedies, inhalers), vitamins and minerals (multi-vitamins, single minerals, single vitamins, tonics, cod liver oil), indigestion preparations (tablets, powders, mixtures), analgesics (Paracetamol, Ibuprofen, Aspirin and other analgesics), and medicated skin products (anti-bacterials, acne treatments, anti-fungal, disinfectants and other), topical OTC medicines (anesthetic products, anti-itch products, antibiotic READ MORE >

Note: Product cover images may vary from those shown

Executive Summary
Market value
Market value forecast
Category segmentation
Geography segmentation
Market share
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market Segmentation
Category segmentation
Geography segmentation
Market share
Market distribution
Market Outlook
Market value forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Bayer AG
GlaxoSmithKline Plc
Johnson & Johnson
Novartis AG
Macroeconomic Indicators
Country Data
Appendix
Methodology
Industry associations
Related research

LIST OF TABLES
Table 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2009–13
Table 2: United Arab Emirates OTC pharmaceuticals market category segmentation: $ million, 2013
Table 3: United Arab Emirates OTC pharmaceuticals market geography segmentation: $ million, 2013
Table 4: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2013
Table 5: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2013
Table 6: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2013–18
Table 7: Bayer AG: key facts
Table 8: Bayer AG: key financials ($)
Table 9: Bayer AG: key financials (€)
Table 10: Bayer AG: key financial ratios
Table 11: GlaxoSmithKline Plc: key facts
Table 12: GlaxoSmithKline Plc: key financials ($)
Table 13: GlaxoSmithKline Plc: key financials (£)
Table 14: GlaxoSmithKline Plc: key financial ratios
Table 15: Johnson & Johnson: key facts
Table 16: Johnson & Johnson: key financials ($)
Table 17: Johnson & Johnson: key financial ratios
Table 18: Novartis AG: key facts
Table 19: Novartis AG: key financials ($)
Table 20: Novartis AG: key financial ratios
Table 21: United Arab Emirates size of population (million), 2009–13
Table 22: United Arab Emirates gdp (constant 2005 prices, $ billion), 2009–13
Table 23: United Arab Emirates gdp (current prices, $ billion), 2009–13
Table 24: United Arab Emirates inflation, 2009–13
Table 25: United Arab Emirates consumer price index (absolute), 2009–13
Table 26: United Arab Emirates exchange rate, 2009–13

LIST OF FIGURES
Figure 1: United Arab Emirates OTC pharmaceuticals market value: $ million, 2009–13
Figure 2: United Arab Emirates OTC pharmaceuticals market category segmentation: % share, by value, 2013
Figure 3: United Arab Emirates OTC pharmaceuticals market geography segmentation: % share, by value, 2013
Figure 4: United Arab Emirates OTC pharmaceuticals market share: % share, by value, 2013
Figure 5: United Arab Emirates OTC pharmaceuticals market distribution: % share, by value, 2013
Figure 6: United Arab Emirates OTC pharmaceuticals market value forecast: $ million, 2013–18
Figure 7: Forces driving competition in the OTC pharmaceuticals market in United Arab Emirates, 2013
Figure 8: Drivers of buyer power in the OTC pharmaceuticals market in United Arab Emirates, 2013
Figure 9: Drivers of supplier power in the OTC pharmaceuticals market in United Arab Emirates, 2013
Figure 10: Factors influencing the likelihood of new entrants in the OTC pharmaceuticals market in United Arab Emirates, 2013
Figure 11: Factors influencing the threat of substitutes in the OTC pharmaceuticals market in United Arab Emirates, 2013
Figure 12: Drivers of degree of rivalry in the OTC pharmaceuticals market in United Arab Emirates, 2013
Figure 13: Bayer AG: revenues & profitability
Figure 14: Bayer AG: assets & liabilities
Figure 15: GlaxoSmithKline Plc: revenues & profitability
Figure 16: GlaxoSmithKline Plc: assets & liabilities
Figure 17: Johnson & Johnson: revenues & profitability
Figure 18: Johnson & Johnson: assets & liabilities
Figure 19: Novartis AG: revenues & profitability
Figure 20: Novartis AG: assets & liabilities

Note: Product cover images may vary from those shown

GlaxoSmithKline Plc, Johnson & Johnson, Novartis AG and WellSpring Pharmaceuticals

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos